Opportunities Preloader

Please Wait.....

Report

Neurological Biomarkers Market By Type (Genomic, Proteomic, Metabolomic, Others), By Application (Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease): Global Opportunity Analysis and Industry Forecast, 2021-2031

Market Report I 2022-09-01 I 141 Pages I Allied Market Research


Neurological biomarkers are measurable indicators of biological state or condition of patients suffering from neurodegenerative diseases. Brain diseases require plenty of markers to reflect the metabolic impairment of different brain cells. The recent introduction of the metabolomic approach helps the study of neurological diseases based on profiling a multitude of biochemical components related to brain metabolism.
Major factors driving growth of the neurological biomarkers market include increase in geriatric population that are prone to neurological diseases, rise in head injuries, rise in prevalence of Alzheimer's disease, Parkinson's disease, and multiple Sclerosis. For instance, according to the latest WHO data published in 2020 Parkinson's disease deaths in Australia reached 2,036 or 1.49% of total deaths. The age adjusted Death Rate is 3.35 per 100,000 of population ranks Australia #131 in the world. According to WHO update 2022, globally, disability and death due to Parkinson's disease are increasing faster than for any other neurological disorder.
For instance, according to National Multiple Sclerosis Society 2019, between 750,000 and 1 million people in the U.S. over the age of 18 are living with MS. There are more people living with MS in the Northeast and Midwest than in the South. The rates of MS have increased worldwide since 1955. The first report of MS in the U.S. was published in 1976 and found 123,00 cases. A study from 1990 found 300,000 cases of MS. This compares to the estimated 750,000 to 1 million cases in 2019.
Moreover, neurology is one of the disciplines where personalized medicine has been emerging as an important part of treatment methods for Alzheimer's, Parkinson's and Multiple Sclerosis. Neurological biomarkers find a varied scope in personalized medicine, which eventually spurs the demand for diagnosis by incorporating neurological biomarkers. Therefore, rise in the demand for personalized medicine boost the growth of neurological biomarkers market.
Furthermore, increase in demand for minimally invasive procedures propels the adoption of neurological biomarkers product. In addition, technological advancements; launch of various products; strategies among key players such as acquisition, collaboration, and agreement drive the growth of the neurological biomarkers market. For instance, in June 2021, Genentech, a member of the Roche Group, and its parent company, Roche Holding AG, announced a partnership with University of California, San Francisco (UCSF) and UC Berkeley to speed up the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system (CNS) such as Alzheimer's, Parkinson's, Huntington's, Amyotrophic lateral sclerosis (ALS) and autism. UCSF and UC Berkeley had received up to $53 million from Genentech over the course of the 10-year collaboration.
However, the emerging ethical issues regarding early diagnosis of Alzheimer's disease, Parkinson's disease, and multiple Sclerosis is expected to impede the market growth. strict government regulations and high cost for neurological biomarkers products also restrain the market growth.
Furthermore, healthcare business is predicted to witness growth, owing increase in focus on developing cost-effective biomarker testing increase in patient population, and rise in demand for non-invasive diagnostic techniques for Alzheimer's and Parkinson's, increase in R&D investments in drug discovery & development, and rise in awareness regarding neurological biomarker. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.
The neurological biomarkers market is segmented on the basis of type, application, and region. On the basis of type, the market is classified into genomic, proteomic, metabolomic, and others. By application, the market is segregated into Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Region wise, the market is analyzed across North America (the U.S., and Canada), Europe (Germany, France, the UK, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and Rest of LAMEA).
Major players profiled in the report are Biomerieux, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck KGAA, Myriad Genetics, Inc., Neurobio, Perkinelmer Inc., Quanterix, Shimadzu Corporation, Thermo Fisher Scientific, Inc.
KEY BENEFITS FOR STAKEHOLDERS
This report provides an extensive analysis of the current and emerging market trends and dynamics in the diabetic nephropathy market to identify the prevailing opportunities
This study presents the competitive landscape of the global market to predict the competitive environment across various regions
Comprehensive analysis of factors that drive and restrict the market growth is provided
Region & country wise analysis is provided to understand the market trends and dynamics
Key Market Segments
By Type
? Genomic
? Proteomic
? Metabolomic
? Others
By Application
? Parkinson's Disease
? Alzheimer's Disease
? Multiple Sclerosis
By Region
? North America
? U.S.
? Canada
? Europe
? Germany
? France
? UK
? Rest Of Europe
? Asia-Pacific
? Japan
? China
? India
? Rest Of Asia-Pacific
? LAMEA
? Brazil
? Saudi Arabia
? Rest Of LAMEA
? Key Market Players
? F. HOFFMANN-LA ROCHE LTD.
? Bio-Rad Laboratories, Inc.
? merck kgaa, darmstadt, germany
? PERKINELMER INC.
? shimadzu corporation
? Thermo Fisher Scientific, Inc.
? Quanterix
? Neurobio
? bioMerieux
? MYRIAD RBM (MYRIAD GENETICS, INC.)

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: NEUROLOGICAL BIOMARKERS MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Genomic
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Proteomic
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Metabolomic
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Others
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Alzheimer's Disease
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Multiple Sclerosis
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Parkinson's Disease
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: NEUROLOGICAL BIOMARKERS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Type
6.2.3 North America Market size and forecast, by Application
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Type
6.2.4.1.2 Market size and forecast, by Application
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Type
6.2.4.2.2 Market size and forecast, by Application
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Type
6.3.3 Europe Market size and forecast, by Application
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Type
6.3.4.1.2 Market size and forecast, by Application
6.3.4.2 France
6.3.4.2.1 Market size and forecast, by Type
6.3.4.2.2 Market size and forecast, by Application
6.3.4.3 UK
6.3.4.3.1 Market size and forecast, by Type
6.3.4.3.2 Market size and forecast, by Application
6.3.4.4 Rest of Europe
6.3.4.4.1 Market size and forecast, by Type
6.3.4.4.2 Market size and forecast, by Application
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Type
6.4.3 Asia-Pacific Market size and forecast, by Application
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Market size and forecast, by Type
6.4.4.1.2 Market size and forecast, by Application
6.4.4.2 China
6.4.4.2.1 Market size and forecast, by Type
6.4.4.2.2 Market size and forecast, by Application
6.4.4.3 India
6.4.4.3.1 Market size and forecast, by Type
6.4.4.3.2 Market size and forecast, by Application
6.4.4.4 Rest of Asia-Pacific
6.4.4.4.1 Market size and forecast, by Type
6.4.4.4.2 Market size and forecast, by Application
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Type
6.5.3 LAMEA Market size and forecast, by Application
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Type
6.5.4.1.2 Market size and forecast, by Application
6.5.4.2 Saudi Arabia
6.5.4.2.1 Market size and forecast, by Type
6.5.4.2.2 Market size and forecast, by Application
6.5.4.3 Rest of LAMEA
6.5.4.3.1 Market size and forecast, by Type
6.5.4.3.2 Market size and forecast, by Application
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 F. HOFFMANN-LA ROCHE LTD.
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Bio-Rad Laboratories, Inc.
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 merck kgaa, darmstadt, germany
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 PERKINELMER INC.
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 shimadzu corporation
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Thermo Fisher Scientific, Inc.
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Quanterix
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Neurobio
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 bioMerieux
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 MYRIAD RBM (MYRIAD GENETICS, INC.)
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 2. NEUROLOGICAL BIOMARKERS MARKET, FOR GENOMIC, BY REGION, 2021-2031 ($MILLION)
TABLE 3. NEUROLOGICAL BIOMARKERS MARKET FOR GENOMIC, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. NEUROLOGICAL BIOMARKERS MARKET, FOR PROTEOMIC, BY REGION, 2021-2031 ($MILLION)
TABLE 5. NEUROLOGICAL BIOMARKERS MARKET FOR PROTEOMIC, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. NEUROLOGICAL BIOMARKERS MARKET, FOR METABOLOMIC, BY REGION, 2021-2031 ($MILLION)
TABLE 7. NEUROLOGICAL BIOMARKERS MARKET FOR METABOLOMIC, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. NEUROLOGICAL BIOMARKERS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 9. NEUROLOGICAL BIOMARKERS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 11. NEUROLOGICAL BIOMARKERS MARKET, FOR ALZHEIMER'S DISEASE, BY REGION, 2021-2031 ($MILLION)
TABLE 12. NEUROLOGICAL BIOMARKERS MARKET FOR ALZHEIMER'S DISEASE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. NEUROLOGICAL BIOMARKERS MARKET, FOR MULTIPLE SCLEROSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 14. NEUROLOGICAL BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. NEUROLOGICAL BIOMARKERS MARKET, FOR PARKINSON'S DISEASE, BY REGION, 2021-2031 ($MILLION)
TABLE 16. NEUROLOGICAL BIOMARKERS MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. NEUROLOGICAL BIOMARKERS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 18. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 19. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 20. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. U.S. NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 22. U.S. NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 23. CANADA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 24. CANADA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 25. EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 26. EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 27. EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 28. GERMANY NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 29. GERMANY NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 30. FRANCE NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 31. FRANCE NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 32. UK NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 33. UK NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 34. REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 35. REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 36. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 37. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 38. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 39. JAPAN NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 40. JAPAN NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 41. CHINA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 42. CHINA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 43. INDIA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 44. INDIA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 45. REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 46. REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 47. LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 49. LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 50. BRAZIL NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 51. BRAZIL NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 52. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 53. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 54. REST OF LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 55. REST OF LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 56.F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 57.F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
TABLE 58.F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 59.F. HOFFMANN-LA ROCHE LTD.: NET SALES,
TABLE 60.F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 61.BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 62.BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
TABLE 63.BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 64.BIO-RAD LABORATORIES, INC.: NET SALES,
TABLE 65.BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
TABLE 66.MERCK KGAA, DARMSTADT, GERMANY: COMPANY SNAPSHOT
TABLE 67.MERCK KGAA, DARMSTADT, GERMANY: OPERATING SEGMENTS
TABLE 68.MERCK KGAA, DARMSTADT, GERMANY: PRODUCT PORTFOLIO
TABLE 69.MERCK KGAA, DARMSTADT, GERMANY: NET SALES,
TABLE 70.MERCK KGAA, DARMSTADT, GERMANY: KEY STRATERGIES
TABLE 71.PERKINELMER INC.: COMPANY SNAPSHOT
TABLE 72.PERKINELMER INC.: OPERATING SEGMENTS
TABLE 73.PERKINELMER INC.: PRODUCT PORTFOLIO
TABLE 74.PERKINELMER INC.: NET SALES,
TABLE 75.PERKINELMER INC.: KEY STRATERGIES
TABLE 76.SHIMADZU CORPORATION: COMPANY SNAPSHOT
TABLE 77.SHIMADZU CORPORATION: OPERATING SEGMENTS
TABLE 78.SHIMADZU CORPORATION: PRODUCT PORTFOLIO
TABLE 79.SHIMADZU CORPORATION: NET SALES,
TABLE 80.SHIMADZU CORPORATION: KEY STRATERGIES
TABLE 81.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 82.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
TABLE 83.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
TABLE 84.THERMO FISHER SCIENTIFIC, INC.: NET SALES,
TABLE 85.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
TABLE 86.QUANTERIX: COMPANY SNAPSHOT
TABLE 87.QUANTERIX: OPERATING SEGMENTS
TABLE 88.QUANTERIX: PRODUCT PORTFOLIO
TABLE 89.QUANTERIX: NET SALES,
TABLE 90.QUANTERIX: KEY STRATERGIES
TABLE 91.NEUROBIO: COMPANY SNAPSHOT
TABLE 92.NEUROBIO: OPERATING SEGMENTS
TABLE 93.NEUROBIO: PRODUCT PORTFOLIO
TABLE 94.NEUROBIO: NET SALES,
TABLE 95.NEUROBIO: KEY STRATERGIES
TABLE 96.BIOMERIEUX: COMPANY SNAPSHOT
TABLE 97.BIOMERIEUX: OPERATING SEGMENTS
TABLE 98.BIOMERIEUX: PRODUCT PORTFOLIO
TABLE 99.BIOMERIEUX: NET SALES,
TABLE 100.BIOMERIEUX: KEY STRATERGIES
TABLE 101.MYRIAD RBM (MYRIAD GENETICS, INC.): COMPANY SNAPSHOT
TABLE 102.MYRIAD RBM (MYRIAD GENETICS, INC.): OPERATING SEGMENTS
TABLE 103.MYRIAD RBM (MYRIAD GENETICS, INC.): PRODUCT PORTFOLIO
TABLE 104.MYRIAD RBM (MYRIAD GENETICS, INC.): NET SALES,
TABLE 105.MYRIAD RBM (MYRIAD GENETICS, INC.): KEY STRATERGIES

LIST OF FIGURES
FIGURE 1.NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION
FIGURE 2.NEUROLOGICAL BIOMARKERS MARKET,2021-2031
FIGURE 3.NEUROLOGICAL BIOMARKERS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.NEUROLOGICAL BIOMARKERS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.NEUROLOGICAL BIOMARKERS MARKET,BY TYPE,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GENOMIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PROTEOMIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF METABOLOMIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
FIGURE 17.NEUROLOGICAL BIOMARKERS MARKET,BY APPLICATION,2021(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ALZHEIMER'S DISEASE NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF MULTIPLE SCLEROSIS NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF PARKINSON'S DISEASE NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
FIGURE 21.NEUROLOGICAL BIOMARKERS MARKET BY REGION,2021
FIGURE 22.U.S. NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
FIGURE 23.CANADA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
FIGURE 24.GERMANY NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
FIGURE 25.FRANCE NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
FIGURE 26.UK NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
FIGURE 27.REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
FIGURE 28.JAPAN NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
FIGURE 29.CHINA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
FIGURE 30.INDIA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
FIGURE 31.REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
FIGURE 32.BRAZIL NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
FIGURE 33.SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
FIGURE 34.REST OF LAMEA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
FIGURE 35. TOP WINNING STRATEGIES, BY YEAR
FIGURE 36. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 37. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 38.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 39.COMPETITIVE DASHBOARD
FIGURE 40.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 41.F. HOFFMANN-LA ROCHE LTD..: NET SALES ,($MILLION)
FIGURE 42.BIO-RAD LABORATORIES, INC..: NET SALES ,($MILLION)
FIGURE 43.MERCK KGAA, DARMSTADT, GERMANY.: NET SALES ,($MILLION)
FIGURE 44.PERKINELMER INC..: NET SALES ,($MILLION)
FIGURE 45.SHIMADZU CORPORATION.: NET SALES ,($MILLION)
FIGURE 46.THERMO FISHER SCIENTIFIC, INC..: NET SALES ,($MILLION)
FIGURE 47.QUANTERIX.: NET SALES ,($MILLION)
FIGURE 48.NEUROBIO.: NET SALES ,($MILLION)
FIGURE 49.BIOMERIEUX.: NET SALES ,($MILLION)
FIGURE 50.MYRIAD RBM (MYRIAD GENETICS, INC.).: NET SALES ,($MILLION)

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE